BioTuesdays

Tag - NPCE

Neuropace

SVB Leerink starts NeuroPace at OP; PT $25

SVB Leerink initiated coverage of Neuropace (NASDAQ:NPCE) with an “outperform” rating and $25 price target. The stock closed at $20.91 on May 14. “To us, NeuroPace represents a top-tier growth profile SMID-cap MedTech...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.